Open in Screener

ROIV

Roivant Sciences Ltd

Mar 30 • 04:00PM ET

26.41

-0.11 -0.41 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: VTI IJH VB VBK VXF XMMO IBB MDY XBI SPMD

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	31.76%	Shs Outstand	709.69M	Perf Week	-5.44%
Market Cap	18.90B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-10.79%	Shs Float	488.39M	Perf Month	-8.74%
Enterprise Value	15.18B	PEG	-	EPS next Q	-0.29	Inst Own	67.19%	Short Float	4.79%	Perf Quarter	18.80%
Income	-809.24M	P/S	1420.11	EPS this Y	-366.11%	Inst Trans	2.15%	Short Ratio	3.67	Perf Half Y	74.09%
Sales	13.31M	P/B	4.39	EPS next Y	-5.86%	ROA	-14.69%	Short Interest	23.39M	Perf YTD	21.71%
Book/sh	6.02	P/C	4.17	EPS next 5Y	-	ROE	-17.11%	52W High	30.33 -12.92%	Perf Year	154.43%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-18.53%	52W Low	8.73 202.52%	Perf 3Y	261.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	60.46%	Volatility	3.66% 3.57%	Perf 5Y	168.67%
Dividend TTM	-	EV/Sales	1140.72	EPS Y/Y TTM	-751.06%	Oper. Margin	-9130.53%	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.66	Sales Y/Y TTM	-86.36%	Profit Margin	-6079.94%	RSI (14)	41.36	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	30.66	EPS Q/Q	-262.80%	SMA20	-6.28%	Beta	1.22	Target Price	34.27
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.83%	SMA50	0.34%	Rel Volume	0.67	Prev Close	26.52
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	41.57%	Avg Volume	6.38M	Price	26.41
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.41% -60.65%	Trades		Volume	4,283,855	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Outperform	$35
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-28-26 03:00PM	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis (GlobeNewswire)
Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Loading…
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga)
02:00PM	Loading…
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire)
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:01PM	Loading…
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily)
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzgerald Meghan	Director	Mar 26 '26	Option Exercise	8.80	70,000	616,000	112,963	Mar 30 09:01 PM
Fitzgerald Meghan	Director	Mar 26 '26	Sale	27.45	70,000	1,921,500	42,963	Mar 30 09:01 PM
MEGHAN FITZGERALD	Director	Mar 26 '26	Proposed Sale	27.45	70,000	1,921,458		Mar 26 04:14 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Mar 19 06:36 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Sale	28.24	200,000	5,648,000	1,647,546	Mar 19 06:36 PM
Epperly Melissa B,	Director	Mar 16 '26	Sale	28.68	41,861	1,200,573	15,804	Mar 18 06:23 PM
Venker Eric	Officer	Mar 17 '26	Proposed Sale	28.24	200,000	5,648,836		Mar 17 04:17 PM
MELISSA B EPPERLY	Director	Mar 16 '26	Proposed Sale	28.68	41,861	1,200,498		Mar 16 04:04 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM
Sukhatme Mayukh	Officer	Feb 09 '26	Proposed Sale	26.47	339,441	8,985,276		Feb 09 04:13 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM

Open in Screener

THC

Tenet Healthcare Corp

Mar 30 • 04:00PM ET

188.00

-3.86 -2.01 %

Healthcare • Medical Care Facilities • USA • NYSE

THC Tenet Healthcare Corp daily Stock Chart

Peers: HCA UHS CYH ACHC SEM ADUS ENSG EHC SGRY HCSG

| Held by: VTI IJH VB VBR VXF MDY COWZ IJK VFLO SPMD

Index	-	P/E	12.14	EPS (ttm)	15.49	Insider Own	1.13%	Shs Outstand	86.95M	Perf Week	-7.58%
Market Cap	16.35B	Forward P/E	10.70	EPS next Y	17.56	Insider Trans	-8.56%	Shs Float	85.98M	Perf Month	-21.47%
Enterprise Value	32.65B	PEG	1.78	EPS next Q	4.16	Inst Own	97.65%	Short Float	2.89%	Perf Quarter	-6.28%
Income	1.41B	P/S	0.77	EPS this Y	2.26%	Inst Trans	-0.20%	Short Ratio	2.42	Perf Half Y	-6.93%
Sales	21.31B	P/B	3.87	EPS next Y	2.36%	ROA	4.80%	Short Interest	2.49M	Perf YTD	-5.39%
Book/sh	48.53	P/C	5.67	EPS next 5Y	6.02%	ROE	33.54%	52W High	247.21 -23.95%	Perf Year	41.20%
Cash/sh	33.15	P/FCF	6.46	EPS past 3/5Y	60.90% 32.77%	ROIC	7.67%	52W Low	109.82 71.18%	Perf 3Y	226.39%
Dividend Est.	-	EV/EBITDA	7.59	Sales past 3/5Y	3.58% 3.85%	Gross Margin	16.14%	Volatility	3.53% 4.34%	Perf 5Y	253.72%
Dividend TTM	-	EV/Sales	1.53	EPS Y/Y TTM	-52.04%	Oper. Margin	16.14%	ATR (14)	8.56	Perf 10Y	549.84%
Dividend Ex-Date	-	Quick Ratio	1.68	Sales Y/Y TTM	3.12%	Profit Margin	6.60%	RSI (14)	27.80	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.76	EPS Q/Q	27.24%	SMA20	-13.54%	Beta	1.50	Target Price	262.71
Payout	0.00%	Debt/Eq	3.42	Sales Q/Q	8.97%	SMA50	-11.71%	Rel Volume	0.94	Prev Close	191.86
Employees	99000	LT Debt/Eq	3.35	Earnings	Feb 11 BMO	SMA200	-3.54%	Avg Volume	1.03M	Price	188.00
IPO	Apr 28, 1971	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.62% 1.01%	Trades		Volume	955,333	Change	-2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Resumed	Goldman	Buy	$224
Jul-28-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-29-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$195
Apr-15-25	Downgrade	Robert W. Baird	Outperform → Neutral	$137
Mar-26-25	Initiated	Morgan Stanley	Overweight	$165
Feb-26-25	Initiated	TD Cowen	Buy	$175
Dec-17-24	Resumed	JP Morgan	Overweight	$175
Dec-16-24	Downgrade	Goldman	Buy → Neutral	$196 → $140
Nov-25-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$205 → $150
Nov-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$195
Oct-11-24	Initiated	KeyBanc Capital Markets	Overweight	$200
May-30-24	Initiated	Robert W. Baird	Outperform	$153
Mar-27-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$122
Mar-06-24	Initiated	Barclays	Overweight	$113
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight	$73
Apr-19-23	Initiated	JP Morgan	Overweight	$72
Jun-17-22	Initiated	Loop Capital	Buy	$80
Mar-29-22	Initiated	Wells Fargo	Overweight	$100
Feb-10-22	Upgrade	UBS	Neutral → Buy	$83 → $111
Feb-09-22	Upgrade	Truist	Hold → Buy	$90

Show Previous Ratings

Mar-29-26 06:00AM	Judicial showdown looms as Supreme Court reviews Trumps birthright ban (Investing.com)
Mar-06-26 04:41PM	Tenet Reports Voluntary Dismissal of U.S. Securities Class Action Lawsuit (TMX Newsfile)
02:00PM	Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know (StockStory)
09:00AM	Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-04-26 02:19PM	'AI Winner' HCA, Stock Of The Day, Gets Healthy With Palantir (Investor's Business Daily)
09:04AM	Loading…
09:04AM	SEM's $16.50 Take-Private Moment: Undervalued or Perfectly Timed? (Zacks)
09:00AM	Tenet to Participate in the Barclays 28th Annual Global Healthcare Conference (Business Wire)
Feb-27-26 06:48AM	How Is HCA Healthcare's Stock Performance Compared to Other Healthcare Providers Stocks? (Barchart)
Feb-26-26 11:53PM	Here's What Analysts Are Saying About Tenet Healthcare Corporation (THC) Post Earnings (Insider Monkey)
12:39PM	Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs (Zacks)
Feb-25-26 09:40AM	Here's Why Tenet Healthcare (THC) is a Strong Value Stock (Zacks)
Feb-24-26 08:30AM	If You Invested $1000 in Tenet Healthcare a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
01:23AM	Tenet Healthcare (THC) Benefiting from Capital Return Potential, Says Wells Fargo (Insider Monkey)
Feb-20-26 11:00AM	Community Health Systems Q4 Earnings Call Highlights (MarketBeat)
09:59AM	Pediatrix Medical Q4 Earnings Miss Estimates Despite Declining Costs (Zacks)
12:34PM	Loading…
Feb-19-26 12:34PM	Community Health Q4 Earnings Beat Estimates on Lower Expenses (Zacks)
09:00AM	Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-18-26 12:35AM	The 5 Most Interesting Analyst Questions From Tenet Healthcare's Q4 Earnings Call (StockStory)
Feb-13-26 05:00PM	Top Stock Reports for Micron Technology, Goldman Sachs & Verizon (Zacks)
Feb-12-26 11:21AM	Tenet Healthcare Beats Q4 Earnings: But 2026 EBITDA Margin May Decline (Zacks)
07:28AM	Tenet expects $250M hit from loss of ACA subsidies this year (Healthcare Dive)
06:40AM	Company News for Feb 12, 2026 (Zacks)
12:31AM	THC Q4 Deep Dive: Tech-Driven Efficiency and Ambulatory Expansion Offset Exchange Headwinds (StockStory)
Feb-11-26 10:37PM	Tenet Healthcare Q4 Earnings Call Highlights (MarketBeat)
08:13PM	Analyst Report: Tenet Healthcare Corporation (Morningstar Research)
04:05PM	Tenet Healthcare Corp (THC) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ... (GuruFocus.com)
12:34PM	Tenet Healthcare Quarterly Profit Surges As Hospital, Surgery Demand Grows (Benzinga)
12:32PM	Tenet Healthcare Corporation Q4 2025 Earnings Call Summary (Moby)
09:30AM	Compared to Estimates, Tenet (THC) Q4 Earnings: A Look at Key Metrics (Zacks)
07:55AM	Tenet Healthcare (THC) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:08AM	Loading…
07:08AM	Tenet Healthcare Guides FY26 In Line With Estimates - Update (RTT News)
07:02AM	Tenet: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Tenet Healthcare (NYSE:THC) Surprises With Q4 CY2025 Sales (StockStory)
06:45AM	Tenet Reports Strong Fourth Quarter and FY 2025 Results; Provides 2026 Financial Outlook (Business Wire)
Feb-10-26 12:23PM	Will Lower Patient Days Affect Tenet Healthcare's Q4 Earnings? (Zacks)
Feb-09-26 10:07PM	Tenet Healthcare (THC) Q4 Earnings: What To Expect (StockStory)
Feb-06-26 09:21AM	Profit Therapy: 3 Medical Stocks Ready to Deliver Q4 Beat (Zacks)
Feb-05-26 09:45AM	Tenet Healthcare (THC) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Feb-04-26 12:10PM	Will Tenet (THC) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:40AM	Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Feb-03-26 07:00PM	Tenet Announces Update to OSC Disclosure Record Review and Partial Revocation Application of Failure to File Cease Trade Order (TMX Newsfile)
06:00PM	Why the Market Dipped But Tenet Healthcare (THC) Gained Today (Zacks)
03:02AM	Tenet Healthcare Details $2.65B Conifer-CommonSpirit Deal, Flags Share Buybacks and AI Push (MarketBeat)
Feb-02-26 06:45AM	Tenet Announces Accretive Transaction and Previews Strong 2025 Results (Business Wire)
04:03AM	Tenet regains full ownership in RCM subsidiary Conifer as CommonSpirit exits (Healthcare Dive)
Jan-29-26 09:00AM	Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know (Zacks)
Jan-22-26 09:30AM	Wall Street Analysts Think Tenet (THC) Is a Good Investment: Is It? (Zacks)
Jan-21-26 08:14PM	Analyst Report: Tenet Healthcare Corporation (Morningstar Research)
Jan-20-26 06:15PM	Tenet Healthcare (THC) Stock Moves -1.77%: What You Should Know (Zacks)
Jan-15-26 03:10PM	Trump unveils his 'Great Healthcare Plan.' Analysts don't expect much of an impact. (MarketWatch)
09:00AM	Here is What to Know Beyond Why Tenet Healthcare Corporation (THC) is a Trending Stock (Zacks)
Jan-14-26 06:00PM	Tenet Healthcare (THC) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jan-13-26 05:30AM	Why Healthcare's Stock-Market Winners and Losers Could Soon Trade Places (The Wall Street Journal)
Jan-09-26 05:12AM	Zacks Industry Outlook Highlights Tenet Healthcare, Universal Health Services and Community Health Systems (Zacks)
Jan-08-26 09:34AM	Hospital Industry Reshaping Under Strain: 3 Stocks Worth Watching (Zacks)
Jan-07-26 06:00PM	Tenet Healthcare (THC) Dips More Than Broader Market: What You Should Know (Zacks)
09:45AM	Here's Why Tenet Healthcare (THC) is a Strong Growth Stock (Zacks)
09:00AM	Tenet to Report its Fourth Quarter 2025 Results on February 11th (Business Wire)
Jan-06-26 09:40AM	Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term (Zacks)
Jan-05-26 10:37PM	Q3 Earnings Highs And Lows: Tenet Healthcare (NYSE:THC) Vs The Rest Of The Hospital Chains Stocks (StockStory)
Dec-26-25 06:00PM	Tenet Healthcare (THC) Gains As Market Dips: What You Should Know (Zacks)
Dec-25-25 02:05PM	Ambulatory Care Drives Tenet Healthcare Corporation (THC)'s Strong Earnings Momentum (Insider Monkey)
Dec-23-25 09:11AM	Ensign Hikes Dividend for the 23rd Straight Year: Is it Sustainable? (Zacks)
Dec-22-25 09:45AM	Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term (Zacks)
Dec-19-25 06:00PM	Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know (Zacks)
06:55AM	Ryder System, Inc. Elects Tammy Romo to Its Board of Directors (Business Wire)
Dec-18-25 12:17PM	Universal Health at 9.6X Earnings: A Rare Discount in Hospital Stocks? (Zacks)
09:00AM	Is Trending Stock Tenet Healthcare Corporation (THC) a Buy Now? (Zacks)
Dec-17-25 01:30PM	How UnitedHealth will be getting 'back to basics' in 2026 (Yahoo Finance Video)
12:19PM	Affordable Care Act: Lawmakers should target healthcare red tape (Yahoo Finance Video)
09:30AM	Tenet (THC) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Dec-10-25 09:50AM	Here's Why Tenet Healthcare (THC) is a Strong Momentum Stock (Zacks)
Dec-05-25 09:45AM	Here's Why Tenet Healthcare (THC) is a Strong Growth Stock (Zacks)
Dec-04-25 09:40AM	Here's Why Tenet Healthcare (THC) is a Strong Value Stock (Zacks)
09:00AM	Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-03-25 09:12AM	Acadia Healthcare Cuts 2025 Outlook After Liability Bomb Went Off (Zacks)
Dec-01-25 11:23AM	Tenet Healthcare Soars 72% YTD: But is the Rally Out of Breath? (Zacks)
Nov-27-25 11:30AM	Tenet (THC) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 08:30AM	If You Invested $1000 in Tenet Healthcare a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Nov-24-25 07:19PM	Analyst Report: Tenet Healthcare Corporation (Morningstar Research)
12:40PM	Why Tenet Healthcare (THC) Stock Is Up Today (StockStory)
Nov-20-25 09:00AM	Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Nov-19-25 09:45AM	Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term (Zacks)
Nov-18-25 09:40AM	Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term (Zacks)
Nov-17-25 07:57PM	Analyst Report: Tenet Healthcare Corporation (Morningstar Research)
06:07AM	Why Tenet Healthcare Could Be the Sector's Big Winner (GuruFocus.com)
Nov-14-25 05:08PM	Larry Robbins Reduces Stake in Tenet Healthcare Corp by 20.69%, Impacting Portfolio by -2.99% (GuruFocus.com)
Nov-13-25 05:16AM	Exclusive-Counter-drone radar firm Chaos raises $510 million in defense tech boom (Reuters)
Nov-12-25 02:05PM	Select Medical Down 5% Despite Q3 Earnings Beat on Patient Volumes (Zacks)
02:31AM	Analyst Report: Tenet Healthcare Corporation (Morningstar Research)
Nov-11-25 01:26PM	Teladoc Health's Q3 Loss Widens Y/Y on Weak BetterHelp Unit (Zacks)
Nov-10-25 04:26PM	Healthcare Stocks Drop After Trump Says ACA Funds Should Go to Public (The Wall Street Journal)
12:55PM	Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat (Zacks)
10:19AM	Health-Insurer Stocks Drop After Trump Says ACA Funds Should Go to Public (The Wall Street Journal)
06:14AM	Stock Market Today: Stocks Futures Jump After Democrats Capitulate, Cast Key Vote Toward Reopening Government (TheStreet)
06:14AM	Stock Market Today: Nasdaq, S&P 500 Leap Over 1% After Congress Inches Closer to Reopening Government (TheStreet)
Nov-06-25 09:00AM	Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know (Zacks)
Nov-04-25 12:38AM	The 5 Most Interesting Analyst Questions From Tenet Healthcare's Q3 Earnings Call (StockStory)

Tenet Healthcare Corp. engages in the provision of healthcare services. It operates through the Hospital Operations and Ambulatory Care segments. The Hospital Operations segment is composed of acute care hospitals, ancillary outpatient facilities, urgent care centers, micro hospitals and physician practices. The Ambulatory Care segment includes the operations of the USPI joint venture and the company's nine Aspen facilities in the United Kingdom. The company was founded in 1969 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arbour Paola M	EVP, Chief Information Officer	Mar 11 '26	Sale	238.43	6,500	1,549,795	29,291	Mar 13 08:00 PM
Arbour Paola M	Officer	Mar 11 '26	Proposed Sale	238.43	6,500	1,549,774		Mar 11 12:36 PM
Arnst Thomas W	EVP, Chief Admin. Officer & GC	Mar 09 '26	Sale	238.85	8,000	1,910,777	12	Mar 10 08:00 PM
Arnst Thomas W	Officer	Mar 09 '26	Proposed Sale	238.85	8,000	1,910,794		Mar 09 01:08 PM
Ramsey R. Scott	Principal Accounting Officer	Mar 02 '26	Sale	232.70	8,017	1,865,577	0	Mar 03 08:00 PM
Arnst Thomas W	EVP, Chief Admin. Officer & GC	Mar 02 '26	Sale	234.04	24,000	5,616,960	8,012	Mar 03 08:00 PM
Arnst Thomas W	Officer	Mar 02 '26	Proposed Sale	234.04	24,000	5,616,933		Mar 02 03:29 PM
West Nadja	Director	Dec 15 '25	Sale	197.47	2,178	430,090	28,480	Dec 17 08:00 PM
West Nadja	Director	Dec 15 '25	Proposed Sale	197.47	2,178	430,097		Dec 15 03:41 PM
Ramsey R. Scott	Principal Accounting Officer	Nov 06 '25	Sale	205.11	13,322	2,732,439	0	Nov 07 08:00 PM
Romo Tammy	Director	Nov 05 '25	Sale	205.20	645	132,354	34,866	Nov 07 08:00 PM
Ramsey R. Scott	Officer	Nov 06 '25	Proposed Sale	205.11	13,322	2,732,412		Nov 06 12:39 PM
Romo Tammy	Director	Nov 03 '25	Sale	200.81	15,099	3,031,969	47,267	Nov 05 08:00 PM
Romo Tammy	Director	Nov 04 '25	Sale	204.07	11,756	2,399,002	35,511	Nov 05 08:00 PM
Romo Tammy	Director	Nov 05 '25	Proposed Sale	205.20	645	132,351		Nov 05 12:45 PM
Romo Tammy	Director	Nov 04 '25	Proposed Sale	204.07	11,756	2,399,032		Nov 04 10:32 AM
Romo Tammy	Director	Nov 03 '25	Proposed Sale	200.80	15,099	3,031,953		Nov 03 04:16 PM
FISHER RICHARD W	Director	Oct 29 '25	Sale	208.43	2,500	521,075	8,792	Oct 31 08:00 PM
FISHER RICHARD W	Director	Oct 29 '25	Proposed Sale	208.43	2,500	521,075		Oct 29 01:20 PM
Sutaria Saumya	CEO	Sep 10 '25	Sale	190.78	78,762	15,026,139	368,683	Sep 12 08:00 PM
Sutaria Saumya	Officer	Sep 10 '25	Proposed Sale	190.78	78,762	15,025,892		Sep 10 03:35 PM
Lynch Christopher S.	Director	Aug 28 '25	Sale	183.44	8	1,468	12,350	Aug 29 08:00 PM
Foo Lisa Y	EVP, Chief Operating Officer	Aug 20 '25	Sale	179.53	8,000	1,436,240	20,878	Aug 22 08:00 PM
Lynch Christopher S.	Director	Aug 19 '25	Sale	176.39	3,952	697,093	12,358	Aug 21 08:00 PM
Foo Lisa Y	Officer	Aug 20 '25	Proposed Sale	179.53	8,000	1,436,279		Aug 20 11:29 AM
FISHER RICHARD W	Director	Jun 05 '25	Sale	173.16	836	144,762	11,292	Jun 06 08:00 PM
Arbour Paola M	EVP, Chief Information Officer	Jun 05 '25	Sale	173.00	7,738	1,338,674	20,110	Jun 06 08:00 PM
Arbour Paola M	Officer	Jun 05 '25	Proposed Sale	173.00	7,738	1,338,674		Jun 05 04:05 PM
FISHER RICHARD W	Director	Jun 05 '25	Proposed Sale	173.15	836	144,758		Jun 05 02:23 PM
BIERMAN JAMES L	Director	May 29 '25	Sale	170.00	4,613	784,210	35,271	May 30 08:00 PM
BIERMAN JAMES L	Director	May 29 '25	Proposed Sale	170.00	4,613	784,210		May 29 10:53 AM
KERREY J ROBERT	Director	May 27 '25	Sale	164.96	1,222	201,581	22,377	May 28 08:00 PM
FISHER RICHARD W	Director	May 27 '25	Sale	165.72	3,077	509,920	12,128	May 28 08:00 PM
BIERMAN JAMES L	Director	May 27 '25	Sale	165.72	1,551	257,032	39,884	May 28 08:00 PM
BIERMAN JAMES L	Director	May 23 '25	Sale	159.58	13,836	2,208,017	41,435	May 27 08:00 PM
KERREY J ROBERT	Director	May 27 '25	Proposed Sale	164.96	1,222	201,582		May 27 05:09 PM
FISHER RICHARD W	Director	May 27 '25	Proposed Sale	165.72	3,077	509,920		May 27 11:18 AM
BIERMAN JAMES L	Director	May 27 '25	Proposed Sale	165.72	1,551	257,032		May 27 10:12 AM
Arnst Thomas W	EVP, Chief Admin. Officer & GC	May 21 '25	Sale	166.00	9,786	1,624,476	0	May 23 08:00 PM
BIERMAN JAMES L	Director	May 23 '25	Proposed Sale	159.58	13,836	2,208,017		May 23 11:09 AM
Arnst Thomas W	Officer	May 21 '25	Proposed Sale	166.00	9,786	1,624,476		May 21 10:10 AM
Arbour Paola M	EVP, Chief Information Officer	May 15 '25	Sale	160.20	6,461	1,035,052	27,848	May 16 08:00 PM
Arbour Paola M	Officer	May 15 '25	Proposed Sale	160.20	6,461	1,035,067		May 15 11:47 AM
KERREY J ROBERT	Director	May 09 '25	Sale	148.50	5,001	742,653	22,377	May 12 08:00 PM
KERREY J ROBERT	Director	May 09 '25	Proposed Sale	148.50	5,001	742,664		May 09 04:24 PM

ROIV

Roivant Sciences Ltd

THC

Tenet Healthcare Corp

Upgrade your Finviz experience